TrialClinical cancer research : an official journal of the American Association for Cancer Research2025

A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.

Won Seog Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.